Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Cancer Cells and Metastasis, and Cancer Immunotherapy and Biomarkers.
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip.
Matching Patients With Cell Surface-Targeted Clinical Trials Using Large Language Models.
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma.
OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance.
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2).
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response.
The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library.
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels.
Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
Figure S9 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer
Figure 6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S7 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Data from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Data from Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer
Figure S8 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Supplementary Figure S1 from Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer
Live Cell Sorting of Differentiated Primary Human Osteoclasts Allows Generation of Transcriptomic Signature Matrix
Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer